Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264). Part 5: Completion of the API Free Base via a Direct Chlorosulfonylation Process-Reference-Cited by-同舟云学术

Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264). Part 5: Completion of the API Free Base via a Direct Chlorosulfonylation Process

Published:2020-10-20 Issue:11 Volume:24 Page:2491-2497
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Di Maso Michael J.¹^ORCID,Ren Hong¹^ORCID,Zhang Si-Wei¹^ORCID,Liu Wenjun¹,Desmond Richard¹,Alwedi Embarek¹^ORCID,Narsimhan Karthik¹,Kalinin Alexei¹,Larpent Patrick¹,Lee Alfred Y.¹^ORCID,Ren Sumei¹,Maloney Kevin M.¹^ORCID

Affiliation:

1. Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.0c00247

Reference28 articles.

1. Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 3: Development of a One-Pot Formylation–Cyclization Sequence to the Diaminopyrimidine Core

2. Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 4: Formylation–Cyclization as a Flow–Batch Process Leads to Significant Improvements in Process Mass Intensity (PMI) and CO Generated versus the Batch–Batch Process

3. ICH Q3C Impurities: Guideline for Residual Solvents (R6). https://database.ich.org/sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf (accessed Nov 26, 2019).

4. Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 1: Introduction and Process Overview

5. Molecular design and synthesis of HCV inhibitors based on thiazolone scaffold

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic Approaches to the New Drugs Approved During 2022;Journal of Medicinal Chemistry;2024-03-15

2. Challenges with retention and recovery of impurities containing acidic moieties during analytical UHPLC method development and validation for gefapixant freebase;Journal of Pharmaceutical and Biomedical Analysis;2024-01

3. Prevalence of Impurity Retention Mechanisms in Pharmaceutical Crystallizations;Organic Process Research & Development;2023-03-24

4. Gefapixant Citrate (MK-7264) Sulfonamide Step Speciation Study: Investigation into Precipitation–Dissolution Events during Addition of Chlorosulfonic Acid;Organic Process Research & Development;2023-02-08

5. Development of a derivatization RP-HPLC method for determination of sulfuryl chloride in chlorosulfonic acid for gefapixant citrate manufacture;Journal of Pharmaceutical and Biomedical Analysis;2022-06